

Liver Fibrosis Drug-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/L40683470D0EN.html

Date: February 2018 Pages: 159 Price: US\$ 3,480.00 (Single User License) ID: L40683470D0EN

Abstracts

Report Summary

Liver Fibrosis Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Liver Fibrosis Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Liver Fibrosis Drug 2013-2017, and development forecast 2018-2023 Main market players of Liver Fibrosis Drug in Europe, with company and product introduction, position in the Liver Fibrosis Drug market Market status and development trend of Liver Fibrosis Drug by types and applications Cost and profit status of Liver Fibrosis Drug, and marketing status Market growth drivers and challenges

The report segments the Europe Liver Fibrosis Drug market as:

Europe Liver Fibrosis Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany United Kingdom France Italy Spain



Benelux

Russia

Europe Liver Fibrosis Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Interferon Maloti Lipid Nucleoside Other

Europe Liver Fibrosis Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Research Center Hospital Clinic

Europe Liver Fibrosis Drug Market: Players Segment Analysis (Company and Product introduction, Liver Fibrosis Drug Sales Volume, Revenue, Price and Gross Margin):

Bird Rock Bio, Inc. Bristol-Myers Squibb Company **Celgene Corporation** Dicerna Pharmaceuticals, Inc. Digna Biotech, S.L. Genfit SA Gilead Sciences, Inc. GNI Group Ltd. HEC Pharm Co., Ltd. Dr. Falk Pharma GmbH LG Life Science LTD. Nitto Denko Corporation Pfizer Inc. **Pharmaxis Limited** Promedior, Inc. Dynavax Technologies Corporation Evotec AG FibroGen, Inc.

Liver Fibrosis Drug-Europe Market Status and Trend Report 2013-2023



In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF LIVER FIBROSIS DRUG

- 1.1 Definition of Liver Fibrosis Drug in This Report
- 1.2 Commercial Types of Liver Fibrosis Drug
- 1.2.1 Interferon
- 1.2.2 Maloti Lipid
- 1.2.3 Nucleoside
- 1.2.4 Other
- 1.3 Downstream Application of Liver Fibrosis Drug
 - 1.3.1 Research Center
 - 1.3.2 Hospital
 - 1.3.3 Clinic
- 1.4 Development History of Liver Fibrosis Drug
- 1.5 Market Status and Trend of Liver Fibrosis Drug 2013-2023
 - 1.5.1 Europe Liver Fibrosis Drug Market Status and Trend 2013-2023
 - 1.5.2 Regional Liver Fibrosis Drug Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Liver Fibrosis Drug in Europe 2013-2017
- 2.2 Consumption Market of Liver Fibrosis Drug in Europe by Regions
- 2.2.1 Consumption Volume of Liver Fibrosis Drug in Europe by Regions
- 2.2.2 Revenue of Liver Fibrosis Drug in Europe by Regions
- 2.3 Market Analysis of Liver Fibrosis Drug in Europe by Regions
- 2.3.1 Market Analysis of Liver Fibrosis Drug in Germany 2013-2017
- 2.3.2 Market Analysis of Liver Fibrosis Drug in United Kingdom 2013-2017
- 2.3.3 Market Analysis of Liver Fibrosis Drug in France 2013-2017
- 2.3.4 Market Analysis of Liver Fibrosis Drug in Italy 2013-2017
- 2.3.5 Market Analysis of Liver Fibrosis Drug in Spain 2013-2017
- 2.3.6 Market Analysis of Liver Fibrosis Drug in Benelux 2013-2017
- 2.3.7 Market Analysis of Liver Fibrosis Drug in Russia 2013-2017
- 2.4 Market Development Forecast of Liver Fibrosis Drug in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Liver Fibrosis Drug in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Liver Fibrosis Drug by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES



- 3.1 Whole Europe Market Status by Types
- 3.1.1 Consumption Volume of Liver Fibrosis Drug in Europe by Types
- 3.1.2 Revenue of Liver Fibrosis Drug in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
- 3.2.1 Market Status by Types in Germany
- 3.2.2 Market Status by Types in United Kingdom
- 3.2.3 Market Status by Types in France
- 3.2.4 Market Status by Types in Italy
- 3.2.5 Market Status by Types in Spain
- 3.2.6 Market Status by Types in Benelux
- 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Liver Fibrosis Drug in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Liver Fibrosis Drug in Europe by Downstream Industry
- 4.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Germany

4.2.2 Demand Volume of Liver Fibrosis Drug by Downstream Industry in United Kingdom

- 4.2.3 Demand Volume of Liver Fibrosis Drug by Downstream Industry in France
- 4.2.4 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Italy
- 4.2.5 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Spain
- 4.2.6 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Benelux
- 4.2.7 Demand Volume of Liver Fibrosis Drug by Downstream Industry in Russia
- 4.3 Market Forecast of Liver Fibrosis Drug in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF LIVER FIBROSIS DRUG

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Liver Fibrosis Drug Downstream Industry Situation and Trend Overview

CHAPTER 6 LIVER FIBROSIS DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

- 6.1 Sales Volume of Liver Fibrosis Drug in Europe by Major Players
- 6.2 Revenue of Liver Fibrosis Drug in Europe by Major Players
- 6.3 Basic Information of Liver Fibrosis Drug by Major Players



6.3.1 Headquarters Location and Established Time of Liver Fibrosis Drug Major Players

6.3.2 Employees and Revenue Level of Liver Fibrosis Drug Major Players

6.4 Market Competition News and Trend

- 6.4.1 Merger, Consolidation or Acquisition News
- 6.4.2 Investment or Disinvestment News
- 6.4.3 New Product Development and Launch

CHAPTER 7 LIVER FIBROSIS DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Bird Rock Bio, Inc.

- 7.1.1 Company profile
- 7.1.2 Representative Liver Fibrosis Drug Product
- 7.1.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bird Rock Bio, Inc.
- 7.2 Bristol-Myers Squibb Company
- 7.2.1 Company profile
- 7.2.2 Representative Liver Fibrosis Drug Product
- 7.2.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers

Squibb Company

7.3 Celgene Corporation

- 7.3.1 Company profile
- 7.3.2 Representative Liver Fibrosis Drug Product
- 7.3.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Celgene

Corporation

- 7.4 Dicerna Pharmaceuticals, Inc.
 - 7.4.1 Company profile
 - 7.4.2 Representative Liver Fibrosis Drug Product
- 7.4.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dicerna

Pharmaceuticals, Inc.

7.5 Digna Biotech, S.L.

- 7.5.1 Company profile
- 7.5.2 Representative Liver Fibrosis Drug Product
- 7.5.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Digna Biotech, S.L.

7.6 Genfit SA

7.6.1 Company profile

7.6.2 Representative Liver Fibrosis Drug Product



7.6.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Genfit SA

7.7 Gilead Sciences, Inc.

7.7.1 Company profile

7.7.2 Representative Liver Fibrosis Drug Product

7.7.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Gilead Sciences, Inc.

7.8 GNI Group Ltd.

7.8.1 Company profile

7.8.2 Representative Liver Fibrosis Drug Product

7.8.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of GNI Group Ltd.

7.9 HEC Pharm Co., Ltd.

7.9.1 Company profile

7.9.2 Representative Liver Fibrosis Drug Product

7.9.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of HEC Pharm Co., Ltd.

7.10 Dr. Falk Pharma GmbH

7.10.1 Company profile

7.10.2 Representative Liver Fibrosis Drug Product

7.10.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Dr. Falk

Pharma GmbH

7.11 LG Life Science LTD.

7.11.1 Company profile

7.11.2 Representative Liver Fibrosis Drug Product

7.11.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of LG Life Science LTD.

7.12 Nitto Denko Corporation

7.12.1 Company profile

7.12.2 Representative Liver Fibrosis Drug Product

7.12.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Nitto Denko

Corporation

7.13 Pfizer Inc.

7.13.1 Company profile

- 7.13.2 Representative Liver Fibrosis Drug Product
- 7.13.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc.

7.14 Pharmaxis Limited

7.14.1 Company profile

7.14.2 Representative Liver Fibrosis Drug Product

7.14.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Pharmaxis Limited



- 7.15 Promedior, Inc.
 - 7.15.1 Company profile
- 7.15.2 Representative Liver Fibrosis Drug Product
- 7.15.3 Liver Fibrosis Drug Sales, Revenue, Price and Gross Margin of Promedior, Inc.
- 7.16 Dynavax Technologies Corporation
- 7.17 Evotec AG
- 7.18 FibroGen, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF LIVER FIBROSIS DRUG

- 8.1 Industry Chain of Liver Fibrosis Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF LIVER FIBROSIS DRUG

- 9.1 Cost Structure Analysis of Liver Fibrosis Drug
- 9.2 Raw Materials Cost Analysis of Liver Fibrosis Drug
- 9.3 Labor Cost Analysis of Liver Fibrosis Drug
- 9.4 Manufacturing Expenses Analysis of Liver Fibrosis Drug

CHAPTER 10 MARKETING STATUS ANALYSIS OF LIVER FIBROSIS DRUG

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach



- 12.1.1 Research Programs/Design
- 12.1.2 Market Size Estimation
- 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
- 12.2.1 Secondary Sources
- 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Liver Fibrosis Drug-Europe Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/L40683470D0EN.html</u>

> Price: US\$ 3,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/L40683470D0EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970